Real-world data reveal unmet clinical needs in insulin treatment in Asian people with type 2 diabetes: the Joint Asia Diabetes Evaluation (JADE) Register

Alice P. S. Kong MD1,2 | Thomas Lew MD3 | Eric S. H. Lau PhD1,2 | Lee-Ling Lim MBBS1,2,4 | Jothydev Kesavadev MD5 | Weiping Jia MD6 | Wayne H.-H. Sheu MD7 | Leorino Sobrepena MD8 | Alexander T. B. Tan MBChB4 | Thy Khue Nguyen MD9 | Kun-Ho Yoon MD10 | Ke Wang PhD11 | Kamlanathan Kodiappan MBBS12 | Tamás Treuer MD13 | Juliana C. N. Chan MD1,2

1Department of Medicine and Therapeutics, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China
2Asia Diabetes Foundation, Shatin, Hong Kong SAR, China
3Eli Lilly and Company (Taiwan) Inc., Taipei, Taiwan
4Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
5Jothydev’s Diabetes and Research Centre, Kerala, India
6Shanghai Sixth People’s Hospital, Shanghai, China
7Taichung Veterans General Hospital, Taichung, Taiwan
8Heart of Jesus Hospital, San Jose City, Philippines
9MEDIC Medical Centre, Ho Chi Minh City, Vietnam
10St. Mary’s Hospital, College of Medicine, Catholic University of Korea, Seoul, South Korea
11Eli Lilly Suzhou Pharmaceutical Co. Ltd, Shanghai, China
12Eli Lilly and Company, Kuala Lumpur, Malaysia
13Lilly Hungaria Kft, Budapest, Hungary

on behalf of the JADE Collaborative Study Group

Abstract

Aims: To explore the pattern of insulin use and glycaemic control in Asian people with type 2 diabetes, stratified by gender, young-onset diabetes (YOD; diagnosed before age 40 years), and diabetic kidney disease (DKD; estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73m²).

Materials and methods: We conducted a cross-sectional analysis of 97,852 patients from 11 Asian countries/regions (2007–2017) included in the prospective Joint Asia Diabetes Evaluation (JADE) Register.

Results: Among 18,998 insulin users (47% women, mean ± SD age 59.2 ± 11.7 years, diabetes duration 13.2 ± 8.3 years, glycated haemoglobin [HbA1c] 72 ± 21.4 mmol/mol [8.74 ± 1.95%], median total daily insulin dose [TDD] 0.27–0.82 units/kg), 25% and 29.5% had YOD and DKD, respectively. Premixed (44%) and basal-only (42%) insulin were the most common regimens. Despite being more commonly treated with these two regimens with higher insulin dosages, patients with YOD had worse HbA1c levels than their late-onset peers (73 ± 20.5 vs. 71 ± 21.2 mmol/mol [8.82 ± 1.87% vs. 8.66 ± 1.94%]; P < 0.001). Fewer women than men attained an HbA1c level < 53 mmol/mol (7%; 15.7% vs. 17.1%; P = 0.018). Adjusting for age, diabetes duration, TDD, HbA1c, eGFR, and use of oral glucose-lowering drugs at baseline, the odds of self-reported hypoglycaemia were higher in women (vs. men: adjusted odds ratio [aOR] 1.16, 95% confidence interval [CI] 1.05–1.28) and in patients with DKD treated with a premixed regimen (1.81 [95% CI 1.54–2.13] vs. 1.34 [95% CI 1.16–1.54] in non-DKD; Pinteraction < 0.001). Compared to basal-only regimens, premixed and basal-bolus regimens had similar HbA1c reductions but were
More than half of the population with diabetes live in Asia and the largest increases in prevalence are estimated to be in the Western Pacific and South-East Asia regions.1 β-cell dysfunction plays a key role in the development of diabetes in Asians with intermediate hyperglycaemia.2 The low body mass index (BMI) in Asian people is often accompanied by low β-cell function, putting them at high risk of progression to type 2 diabetes, especially in the presence of obesity.3,4

Each individual with diabetes has a unique profile, with age and gender having independent effects on risk profiles, psychosocial needs, and health-related behaviours, which may influence clinical course. While age is a major risk factor for type 2 diabetes, young-onset diabetes (YOD; diagnosed before the age of 40 years) now affects one in five Asian adults.5 Apart from genetic predisposition, lifestyle and environmental factors, such as exposure to endocrine-disrupting pollutants, can induce oxidative stress and strain the pancreatic β cells, increasing the risk of YOD.6,7 In a territory-wide diabetes surveillance database of more than 0.4 million adults with diabetes in Hong Kong, 17% had YOD and spent, on average, 100 nights in hospital before the age of 75 years as a result of cardiovascular-renal diseases, mental illness, and sepsis.8 As many as 20% to 50% of people with type 2 diabetes may experience anxiety, stress, and/or depression, especially women and people with YOD, which may negatively impact adherence with increased risk of poor glycaemic control and hypoglycaemia.8,9 While we observed variations in the attainment of treatment goals across countries, there are persistent care gaps in people with YOD, who often require insulin early. In these patients with long disease duration, a suboptimal cardiometabolic risk profile can lead to 1.2 to 1.6 times higher risk of cardiovascular-renal diseases and premature deaths at any given age, compared to their late-onset peers.5,10–12

Epidemiological surveys and randomized clinical trials have reported a high prevalence of diabetic kidney disease (DKD) in Asia, affecting one in six adults with type 2 diabetes.13–15 In the Hong Kong Renal Register, while 60% of patients receiving renal replacement therapy (RRT) had diabetes as a cause, the most rapid rate of increase of RRT occurred in the age group 45 to 60 years, highlighting the long-term burden of YOD.16 In people with DKD, dose adjustment or discontinuation of oral glucose-lowering drugs, such as metformin and sulphonylureas, because of side effects, is often followed by initiation of insulin therapy.17

Given the high prevalence of YOD and DKD in Asia, as well as the potential effects of gender differences in clinical outcomes, we used a multinational, real-world diabetes register with documentation of clinical and biochemical characteristics using the same protocol to explore the patterns of insulin use and the associations of different insulin regimens with glycaemic control in Asians with type 2 diabetes, stratified by gender, YOD, and DKD status at baseline. We hypothesized that a premixed regimen was associated with lower glycated haemoglobin (HbA1c) level but with higher risk of hypoglycaemia than other insulin regimens in Asian people with type 2 diabetes.
and hypoglycaemia, if any), as well as anthropometric measurements and examination for diabetes-related complications. Participants were considered to have cardiovascular disease (CVD) if they reported a history of coronary heart disease, cerebrovascular disease, or peripheral vascular disease (based on revascularization or ankle-brachial index ≤0.9). Blood and urine samples were collected after 8 to 10 hours of fasting.

In the present analysis, we included data from Asian people with type 2 diabetes aged ≥18 years treated with insulin on registration in the JADE Register between January 1, 2007 and October 31, 2017. Exclusion criteria were: 1) type 1 diabetes, defined as presentation with either diabetic ketoacidosis, unprovoked ketosis, or continuous insulin requirement within 12 months of diagnosis and 2) treatment with either diet/exercise or oral glucose-lowering drugs only. We defined YOD as a diagnosis of type 2 diabetes before the age of 40 years and DKD based on estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m² derived from the creatinine-based Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.

We assessed the frequency and severity of self-reported hypoglycaemia in the past 3 months according to the following: 1) experience of typical symptoms of hypoglycaemia (such as hunger, dizziness, perioral numbness, tremor especially if corrected by carbohydrate intake); 2) frequency of hypoglycaemia (at least daily, at least once weekly, at least once monthly, or less than once monthly); 3) nature of the hypoglycaemic episode (mild, moderate, or severe in terms of impairment of daily activities); and 4) number of severe hypoglycaemic episodes requiring attention by a third party, including medical personnel. All participants gave written informed consent for analysis and reporting of the anonymized data. The study was approved by the Joint Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Committee.

2.1 Statistical analysis

Data are presented as mean ± SD or median (interquartile range [IQR]) for continuous variables with normal or skewed distribution, respectively. Categorical variables are expressed as number and percentages. For continuous variables, we used independent t- or Wilcoxon rank-sum tests for comparing two groups, and one-way ANOVA or the Kruskal–Wallis test for comparing three groups or more. We used the chi-squared test for between-group comparisons of categorical variables.

We performed multivariable linear regression analyses to examine the association between HbA1c and insulin regimens using basal-only regimen as the reference. We adjusted for age, sex, duration of diabetes, country/region, history of CVD, logarithmically transformed and weight-adjusted total daily insulin dose (TDD), eGFR, and use of oral glucose-lowering drugs at baseline, as appropriate. Weight-adjusted TDD is calculated by dividing the total daily basal and bolus insulin dosage by body weight, and expressed in units/kg/d. In the logistic regression analyses where hypoglycaemia (at least once monthly) was the dependent variable, apart from the aforementioned covariables, we also adjusted for HbA1c at baseline. The results were presented as adjusted beta coefficients (β) or adjusted odds ratios (aORs) with 95% confidence intervals (CIs). We tested the modifying effects of gender, YOD (yes/no), and DKD (yes/no) with insulin regimens, on HbA1c and risk of hypoglycaemia using each cross-product term in the regression models, followed by stratified analyses. All statistical tests were conducted using R 3.5.1 (www.r-project.org). A two-sided P value <0.05 was considered statistically significant.

3 RESULTS

3.1 Baseline characteristics

Between 2007 and 2017, 108,637 patients with diabetes (90% had type 2 diabetes) from 11 Asian countries/regions were enrolled in the JADE Register. Among patients with type 2 diabetes, 20,031 were insulin-users, of whom 18,998 had complete insulin data for analysis (Figure S1). Table 1 and Table S2 show the baseline characteristics of the study cohort, stratified by gender, YOD, and DKD at baseline. In the analysed cohort (mean ± SD age 59.2 ± 11.7 years, HbA1c 72 ± 21.4 mmol/mol [8.74 ± 1.95%], BMI 26.3 ± 4.6 kg/m², duration of diabetes 13.2 ± 8.3 years), 47% were men, 24.8% had YOD, and 29.5% had DKD. A total of 44%, 42%, and 10% of the cohort were treated with premixed, basal-only, and basal-bolus regimens, respectively. Nearly 50% of the cohort were treated with organ-protective drugs such as renin-angiotensin system inhibitors and statins. More than 80% of these patients performed self-monitoring of blood glucose.

Compared to men, more women had DKD but with a lower proportion for CVD or HbA1c <53 mmol/mol (7%). The weight-adjusted TDD was also higher in women. Patients with YOD had a higher BMI and a higher proportion of them received basal-bolus and premixed insulin regimens, with a higher weight-adjusted TDD than those with late-onset diabetes. More patients with DKD had coexistent CVD and were treated with premixed insulin than patients without DKD.

3.2 Patterns of insulin use in Asia

Upon stratification by type of insulin regimen, premixed regimen was the preferred regimen in most countries/regions (China, India, Singapore, Philippines, Taiwan, Thailand, and Vietnam; Table S3). Basal-only regimens were most commonly prescribed in Hong Kong, Korea, Indonesia and Malaysia, although basal-bolus regimens were also popular in the latter two countries. The median (IQR) weight-adjusted TDD was 0.60 (0.42–0.90) units/kg/d for premixed regimen and ranged from 0.27 to 0.82 units/kg/d for basal-only, bolus-only, and basal-bolus regimens.

3.3 Quality of glycaemic control

In multivariable linear regression analyses, compared to basal-only, the HbA1c reduction was similar with the use of basal-bolus,
| TABLE 1 | Baseline characteristics of the study cohort, stratified by gender, young-onset diabetes, and diabetic kidney disease (DKD) at baseline |
|----------|----------------------------------------------------------------------------------------------------------------------------------|
| **All patients (n = 18,998)** | **Gender** | **Onset of diabetes** | **DKD at baseline** |
| | | Men (n = 10,047) | Women (n = 8,951) | | Yes (eGFR < 60 mL/min/1.73 m²; n = 5,601) | No (eGFR ≥ 60 mL/min/1.73 m²; n = 13,397) |
| Age, years | 18,998 | 59.2 ± 11.7 | 10,047 | 58.5 ± 11.7 | 8,951 | 59.9 ± 11.6 | <0.001 | 4705 | 52.0 ± 8.4 | 13,247 | 63.3 ± 9.3 | <0.001 |
| Women, n (%) | 18,998 | 8951 (47.1) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Duration of diabetes, years | 17,952 | 13.2 ± 8.3 | 9,476 | 13.9 ± 8.3 | 8,476 | 13.5 ± 8.3 | <0.001 | 4705 | 17.8 ± 9.0 | 13,247 | 11.5 ± 7.4 | <0.001 |
| HbA1c, NGSP (%) | 17,150 | 8.74 ± 1.95 | 9,176 | 8.74 ± 1.99 | 7,974 | 8.75 ± 1.92 | 0.680 | 4317 | 8.82 ± 1.87 | 11,890 | 8.66 ± 1.94 | <0.001 |
| HbA1c, IFCC (mmol/mol) | 17,150 | 72 ± 21.4 | 9,176 | 72 ± 21.7 | 7,974 | 72 ± 21.0 | 0.680 | 4317 | 73 ± 20.5 | 11,890 | 71 ± 21.2 | <0.001 |
| HbA1c < 7 % (53 mmol/mol) | 17,150 | 2,823 (16.5) | 9,176 | 1,568 (17.1) | 7,974 | 1,255 (15.7) | 0.018 | 4317 | 607 (14.1) | 11,890 | 2,091 (17.6) | <0.001 |
| Systolic BP, mmHg | 18,697 | 134 ± 18.5 | 9,905 | 133 ± 18.1 | 8,792 | 134 ± 18.9 | 0.006 | 4643 | 133 ± 17.5 | 13,036 | 11.5 ± 7.4 | <0.001 |
| Diastolic BP, mmHg | 18,665 | 78.1 ± 10.0 | 9,888 | 79.1 ± 9.8 | 7,777 | 77.1 ± 10.0 | <0.001 | 4633 | 78.6 ± 9.7 | 13,018 | 78.0 ± 10.1 | 0.001 |
| Total cholesterol, mmol/L | 15,691 | 4.6 ± 1.2 | 8,248 | 4.5 ± 1.2 | 7,443 | 4.8 ± 1.2 | <0.001 | 4048 | 4.6 ± 1.1 | 10,953 | 4.6 ± 1.2 | 0.583 |
| LDL cholesterol, mmol/L | 16,191 | 2.6 ± 1.2 | 8,620 | 2.6 ± 1.2 | 7,571 | 2.7 ± 1.2 | <0.001 | 4048 | 2.6 ± 1.1 | 11,303 | 2.6 ± 1.2 | 0.017 |
| HDL cholesterol, mmol/L | 16,265 | 1.2 ± 0.4 | 8,628 | 1.1 ± 0.4 | 7,628 | 1.3 ± 0.4 | <0.001 | 4056 | 1.2 ± 0.4 | 11,351 | 1.2 ± 0.4 | 0.101 |
| Triglycerides, mmol/L | 16,443 | 1.5 (1.1–2.1) | 8,766 | 1.5 (1.0–2.1) | 7,677 | 1.5 (1.1–2.1) | 0.840 | 4100 | 1.5 (1.0–2.1) | 11,485 | 1.5 (1.1–2.1) | 0.888 |
| BMI, kg/m² | 18,335 | 26.3 ± 4.6 | 9,734 | 26.1 ± 4.3 | 8,601 | 26.5 ± 4.9 | <0.001 | 4580 | 26.8 ± 4.8 | 12,780 | 26.1 ± 4.5 | <0.001 |
| eGFR, mL/min/1.73 m² | 16,546 | 74.5 ± 28.0 | 8,882 | 75.5 ± 28.0 | 7,664 | 73.4 ± 28.0 | <0.001 | 4137 | 81.9 ± 26.7 | 11,553 | 69.9 ± 26.7 | <0.001 |
| Urine ACR, mg/mmol | 11,023 | 4.2 (1.1–24.0) | 5,689 | 4.3 (1.0–26.4) | 5,136 | 4.1 (1.2–21.8) | 0.840 | 2747 | 3.7 (0.9–21.2) | 7,520 | 4.7 (1.2–26.0) | 0.733 |
| Current smoker, n (%) | 18,722 | 2,025 (10.8) | 9,926 | 1,877 (18.9) | 8,796 | 1,48 (1.7) | <0.001 | 4645 | 521 (11.2) | 13,062 | 1,369 (10.5) | 0.172 |
| CVD, n (%) | 18,998 | 4386 (23.1) | 10,047 | 2612 (26.0) | 8,951 | 1,774 (19.8) | <0.001 | 4705 | 818 (17.4) | 13,247 | 3488 (26.3) | <0.001 |
| DKD, n (%) | 18,998 | 5601 (29.5) | 10,047 | 2837 (28.2) | 8,951 | 2764 (30.9) | <0.001 | 4705 | 1037 (22.0) | 13,247 | 4451 (33.6) | <0.001 |
| Insulin regimen, n (%) | 18,998 | 10,047 | 8,951 | 0.105 | 4705 | 0.105 | 0.001 | 5601 | 0.001 | 13,397 | 0.001 | NA | NA | NA | NA | NA |
| TABLE 1 (Continued) |
|----------------------|
| **All patients** (n = 18,998) | **Gender** | **Onset of diabetes** | **DKD at baseline** |
|                        | **Men** (n = 10,047) | **Women** (n = 8,951) | **P** | **Men** (n = 13,247) | **Women** (n = 13,397) | **P** |
| **Young-onset** (age of diagnosis <40 years; n = 4,705) | | | |
| Basal-only | 7,905 (41.6) | 4,128 (41.1) | 3,777 (42.2) | 1,737 (36.9) | 5,778 (43.6) | 22,67 (40.5) | 5,638 (42.1) |
| Basal-bolus | 1,927 (10.1) | 1,055 (10.5) | 872 (9.7) | 630 (13.4) | 1,131 (8.5) | 551 (9.8) | 1,376 (10.3) |
| Bolus-only | 829 (4.4) | 459 (4.6) | 370 (4.1) | 210 (4.5) | 565 (4.3) | 216 (3.9) | 613 (4.6) |
| Premixed | 8,337 (43.9) | 4,405 (43.8) | 3,932 (43.9) | 2,128 (45.2) | 5,773 (43.6) | 2,567 (45.8) | 5,770 (43.1) |
| **Late-onset** (age of diagnosis ≥40 years; n = 13,247) | | | |
| Basal-only | 6,961 | 0.27 (0.18–0.45) | 3,669 | 0.25 (0.16–0.41) | 3,292 | 0.30 (0.19–0.49) | <0.001 | 15,13 | 0.30 (0.19–0.49) | 5,104 | 0.27 (0.17–0.44) | <0.001 | 1,965 | 0.29 (0.18–0.47) | 4,996 | 0.27 (0.18–0.44) | 0.018 |
| Basal-bolus | 1,715 | 0.82 (0.52–1.28) | 945 | 0.79 (0.51–1.26) | 770 | 0.85 (0.54–1.29) | 0.119 | 568 | 0.89 (0.57–1.39) | 995 | 0.80 (0.50–1.24) | 0.002 | 489 | 0.89 (0.54–1.31) | 1,226 | 0.79 (0.52–1.26) | 0.080 |
| Bolus-only | 726 | 0.58 (0.35–0.91) | 401 | 0.56 (0.34–0.89) | 325 | 0.61 (0.36–0.91) | 0.240 | 180 | 0.59 (0.38–0.94) | 497 | 0.58 (0.33–0.92) | 0.333 | 192 | 0.61 (0.35–0.98) | 534 | 0.56 (0.35–0.87) | 0.256 |
| Premixed | 7,090 | 0.60 (0.42–0.90) | 3,860 | 0.55 (0.39–0.84) | 3,230 | 0.65 (0.45–0.96) | <0.001 | 1,823 | 0.67 (0.44–1.00) | 4,900 | 0.58 (0.41–0.86) | <0.001 | 2,156 | 0.60 (0.44–0.87) | 4,934 | 0.60 (0.40–0.91) | 0.425 |
| Total daily insulin dose, units/kg/d | | | | |
| Basal-only | 18,998 | 4,727 (73.9) | 8,951 | 6,686 (76.7) | <0.001 | 4,705 | 3,801 (80.8) | 13,247 | 9,793 (73.9) | <0.001 | 5,601 | 3,598 (64.2) | 13,397 | 10,694 (79.8) | <0.001 |
| Basal-bolus | 18,998 | 4,761 (47.4) | 8,951 | 4,184 (46.7) | 0.383 | 4,705 | 2,240 (47.6) | 13,247 | 6,466 (48.8) | 0.161 | 5,601 | 3,299 (58.9) | 13,397 | 5,646 (42.1) | <0.001 |
| Bolus-only | 18,998 | 9,354 (49.2) | 8,951 | 4,360 (48.7) | 0.175 | 4,705 | 2,345 (49.8) | 13,247 | 6,707 (50.8) | 0.361 | 5,601 | 3,287 (58.7) | 13,397 | 6,067 (45.3) | <0.001 |
| Premixed | 18,998 | 14,684 (83.3) | 8,375 | 6,944 (82.9) | 0.469 | 4,388 | 3,697 (84.3) | 12,337 | 10,262 (83.2) | 0.106 | 5,310 | 4,557 (85.8) | 12,353 | 10,127 (82.0) | <0.001 |
| On oral glucose-lowering drugs, n (%) | | | | |
| On RAS inhibitors, n (%) | 18,998 | 8951 (47.1) | 8,951 | 4,184 (46.7) | 0.383 | 4,705 | 2,240 (47.6) | 13,247 | 6,466 (48.8) | 0.161 | 5,601 | 3,299 (58.9) | 13,397 | 5,646 (42.1) | <0.001 |
| On statins, n (%) | 18,998 | 9,312 (17.5) | 9,379 | 1,633 (17.4) | 0.785 | 4,432 | 846 (19.1) | 12,409 | 2,148 (17.3) | 0.008 | 5,319 | 1,118 (21.0) | 12,474 | 1,994 (16.0) | <0.001 |

Abbreviations: ACR, albumin:creatinine ratio; BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; DKD, diabetic kidney disease; eGFR, estimated glomerular filtration rate; IFCC, International Federation of Clinical Chemistry and Laboratory Medicine; NA, not applicable; NGSP, National Glycohemoglobin Standardization Program; RAS, renin-angiotensin system; SMBG, self-monitoring of blood glucose.

Data are expressed as mean ± SD or median (interquartile range), unless otherwise indicated.
bolus-only, and premixed regimens (Figure 1). Among patients with DKD, premixed regimen was independently associated with lower mean HbA1c (−2.8 mmol/mol [95% CI −4.4, −1.2] or −0.26% [95% CI −0.40, −0.11]). Younger age, female sex, long disease duration, low eGFR, low baseline HbA1c, history of CVD, and non-use of oral glucose-lowering drugs were associated with increased odds of self-reported hypoglycaemia (Table S4). After adjusting for these covariates and using basal-only regimen as reference, the aORs for hypoglycaemia were 1.88 (95% CI 1.58, 2.23) and 1.65 (95% CI 1.45, 1.88) for basal-bolus and premixed regimens, respectively (Figure 2).

Compared to those without DKD, premixed insulin users with DKD had a lower mean HbA1c (−2.4 mmol/mol [95% CI −3.6, −1.2] vs. −0.3 mmol/mol [95% CI −1.3, 0.8] or −0.22% [95% CI −0.33, −0.11] vs. −0.03% [95% CI −0.12, 0.07]; P_{interaction} = 0.012 [Figure 3A]), but increased odds of self-reported hypoglycaemia (aOR 1.81 [95% CI 1.54, 2.13] vs. 1.34 [95% CI 1.16, 1.54]; P_{interaction} < 0.001 [Figure 3B]). Among patients treated with a basal-bolus regimen, women (aOR 1.92 [95% CI 1.52, 2.41] vs. 1.60 [95% CI 1.29, 1.98] in men; P_{interaction} = 0.758) and patients with YOD (aOR 2.18 [95% CI 1.70, 2.77] vs. 1.80 [95% CI 1.46, 2.20] in those with late-onset diabetes; P_{interaction} = 0.263) showed a similar direction of increased odds of self-reported hypoglycaemia, albeit not statistically significant (Figure 3B).

4 | DISCUSSION

In this JADE Register with detailed information of 97 852 patients with type 2 diabetes recruited from 11 countries/regions in Asia,
one in five patients was treated with insulin with different regimens in different countries. Despite the use of similar or higher insulin dosage (0.3–0.8 units/kg) than that reported in clinical trials, only 17% of these patients achieved an HbA1c level < 53 mmol/mol (7%). Overall, nearly one in five patients reported hypoglycaemia, especially among patients with YOD, women, or those with DKD treated with premixed regimen, after adjusting for confounders. While clinical trials have confirmed the efficacy of multiple medications including insulin therapy in controlled settings, their effectiveness in real-world practice depends on many factors such as access, adherence, and support systems.

In the UK Prospective Diabetes Study (UKPDS), modelling data demonstrated that type 2 diabetes is a progressive disease with 50% loss of pancreatic β-cell function at diagnosis, which continues to decrease regardless of therapy with diet, sulphonylureas, or metformin. Between 1995 and 2007, the US Behavioural Risk Factor Surveillance System reported that 22% of adults aged ≥40 years with type 2 diabetes required insulin therapy. Notably, Asian people are more likely to have renal and β-cell dysfunction and thus, may require insulin therapy earlier than white people to achieve glycaemic control. Apart from high HbA1c and BMI (by Asian criteria), the present cohort had relatively good control of other cardiometabolic risk factors, with nearly half of them treated with organ-protective drugs and >80% of them performing self-monitoring of blood glucose.

Achieving glycaemic and weight control is challenging, especially in those treated with complex insulin regimens which demand high

| Subgroup                        | Adjusted odds ratio (95% CI) | P-value |
|---------------------------------|-----------------------------|---------|
| **Entire cohort**               |                             |         |
| Basal bolus                     | 1.88 (1.58, 2.23)           | <0.001  |
| Bolus-only                      | 1.31 (0.99, 1.73)           | 0.057   |
| Premixed                        | 1.65 (1.45, 1.88)           | <0.001  |
| **With DKD at baseline**        |                             |         |
| Basal bolus                     | 1.43 (1.03, 1.98)           | 0.032   |
| Bolus-only                      | 1.02 (0.62, 1.63)           | 0.936   |
| Premixed                        | 1.87 (1.49, 2.34)           | <0.001  |
| **Without DKD at baseline**     |                             |         |
| Basal bolus                     | 2.02 (1.66, 2.46)           | <0.001  |
| Bolus-only                      | 1.40 (1.01, 1.92)           | 0.037   |
| Premixed                        | 1.49 (1.28, 1.74)           | <0.001  |
| **Young-onset diabetes**        |                             |         |
| Basal bolus                     | 2.23 (1.65, 2.99)           | <0.001  |
| Bolus-only                      | 1.75 (1.03, 2.90)           | 0.034   |
| Premixed                        | 1.66 (1.29, 2.13)           | <0.001  |
| **Late-onset diabetes**         |                             |         |
| Basal bolus                     | 1.73 (1.39, 2.14)           | <0.001  |
| Bolus-only                      | 1.16 (0.82, 1.62)           | 0.378   |
| Premixed                        | 1.62 (1.39, 1.89)           | <0.001  |
| **Women**                       |                             |         |
| Basal bolus                     | 1.95 (1.51, 2.50)           | <0.001  |
| Bolus-only                      | 1.62 (1.07, 2.40)           | 0.021   |
| Premixed                        | 1.69 (1.40, 2.04)           | <0.001  |
| **Men**                         |                             |         |
| Basal bolus                     | 1.81 (1.42, 2.29)           | <0.001  |
| Bolus-only                      | 1.10 (0.73, 1.62)           | 0.625   |
| Premixed                        | 1.61 (1.34, 1.93)           | <0.001  |

**FIGURE 2** Multivariable logistic regression analyses of the associations between different insulin regimens and self-reported hypoglycaemia using basal-only regimen as the reference, stratified by gender, young-onset diabetes (YOD), and diabetic kidney disease (DKD) at baseline. The logistic regression analyses were adjusted for age, sex, duration of diabetes, country/region, glycated haemoglobin (HbA1c; NGSP, %), estimated glomerular filtration rate (eGFR), logarithmically transformed weight-adjusted total daily insulin dose, use of oral glucose-lowering drugs at baseline, and history of cardiovascular disease, as appropriate. Patients with YOD were defined as those with a diagnosis of diabetes before the age of 40 years. CI, confidence interval. DKD was defined as eGFR < 60 mL/min/1.73 m². CI, confidence interval; NGSP, National Glycohemoglobin Standardization Program.
levels of patient participation and self-management. In a global real-world survey, 11% to 13% of insulin-treated patients with either type 1 or type 2 diabetes admitted to having discontinued their insulin intermittently for 1 to 2 months in the past for multiple reasons, including lack of education and support. This real-world evidence points to the importance of patient education and engagement, calling for better psychosocial and behavioural support from the healthcare team (including clinicians and allied health personnel), families, and peers to optimize diabetes care. In this real-world register, which involved mainly hospital-based clinics, premixed and basal-only regimens were most popular, although basal-bolus regimen was also often used in Indonesia and Malaysia. The latest American Diabetes Association/European Association for the Study of Diabetes guidelines emphasize individualized treatment goals and strategies, and that if HbA1c goal is not attained despite the use of multiple oral drugs, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a possible option. That said, because of the high cost of GLP-1RAs, initiation of basal insulin, followed by addition of prandial insulin before the largest meal or switching to twice- or thrice-daily premixed insulin, remains the mainstream therapy. We reported that only 10% of patients were treated with a basal-bolus regimen, probably for reasons of patients' acceptability to multiple injections, patients' fear of hypoglycaemia, lack of support systems, and high treatment costs, especially if the treatment is paid out-of-pocket. The high treatment cost is in part due to the complexity of pricing, procurement, and supply chain of insulin.

FIGURE 3 Modifying effects of gender, young-onset diabetes (YOD), and diabetic kidney disease (DKD) at baseline on the impact of intensive insulin regimens in the entire cohort
For each subgroup, the respective reference groups were: premixed - DKD -; basal-bolus -, YOD -; and basal-bolus -, women. Based on the results from Tables S5 to S8, we included each relevant cross-product item in the linear and logistic regression analyses of the entire cohort, adjusting for age, sex, duration of diabetes, country/region, estimated glomerular filtration rate (eGFR), logarithmically transformed weight-adjusted total daily insulin dose, use of oral glucose-lowering drugs at baseline, and history of cardiovascular disease, as appropriate. For self-reported hypoglycaemia, we also adjusted for glycated haemoglobin (HbA1c) at baseline. Patients with YOD were defined as those with a diagnosis of diabetes before the age of 40 years. DKD was defined as eGFR <60 ml/min/1.73m². CI, confidence interval; NGSP, National Glycohemoglobin Standardization Program.
Despite having lower HbA1c, overall, more patients with DKD treated with premixed insulin reported hypoglycaemia than those without DKD. We and others have reported that DKD is a major risk factor for hypoglycaemia due to multiple factors including reduced renal gluconeogenesis and drug clearance. 30,31 Although we did not record the year of insulin initiation in these patients, patients with DKD had over 10 years of diabetes when the use of insulin analogues and basal-bolus regimen were less popular. 32,33

In this real-world register, more women reported hypoglycaemia than men, after adjusting for confounders. Despite having similar glycaemic control (mean HbA1c 72 mmol/mol [8.7%]), women had a higher BMI by 0.4 kg/m² and a higher weight-adjusted TDD for any insulin regimen compared to men. In a previous analysis, depression was more common in Chinese women than men, with depression being associated with both hypoglycaemia and hyperglycaemia; this was attenuated after adjustment for self-report of non-adherence. 34,35 Although we did not document these psychosocial and behavioural factors in this survey, healthcare providers should be aware of these factors which may be linked to non-adherence. Indeed, the high weight-adjusted TDD in women and patients with YOD and, to some extent, those of DKD, irrespective of insulin regimens, raised the possibility of suboptimal treatment adherence. Increasing insulin dosage without taking into consideration other factors that can influence glycaemic control (e.g., lifestyles, diets, work schedule, emotions) can lead to a cycle of weight gain, insulin resistance, glycaemic variability, and non-adherence, which will increase the complexity of management. 27 As such, the use of team-based care to perform periodic assessment to stratify risk, provide self-management support, and enhance patient–provider communication may help optimize care. 26

In this survey, 4% of patients were treated with bolus-only regimen, although this is not routinely recommended. 19 In a pooled analysis of randomized clinical trials involving patients with suboptimally controlled type 2 diabetes treated with oral glucose-lowering drugs, Asian people had lower fasting plasma glucose but higher HbA1c levels than white people, despite a similar dosage of basal insulin. 36 These findings lent support to the reduced capacity of Asian people to overcome high postprandial glucose excursions, which require additional treatment. 24 In this insulin-treated cohort, 25% of patients had YOD. While 17% of the entire cohort attained HbA1c <53 mmol/mol (7%), only 14% of patients with YOD attained goal, compared to 18% in their late-onset peers. Although more patients with YOD were put on basal-bolus and premixed regimens with higher weight-adjusted TDD than their late-onset peers, they had worse glycaemic control, raising the possibility of non-adherence and suboptimal self-care.

To our knowledge, this is the first and largest real-world type 2 diabetes register using the same protocol for data collection which allows robust comparisons among different care settings. In this analysis, we have demonstrated the different patterns of insulin regimens in Asia where data are relatively scarce. We further identified different quality of glycaemic control with different insulin regimens, which was influenced by gender, YOD, and DKD status, after adjusting for covariables and variances due to countries/regions in our regression analyses.

There are several study limitations. First, despite the proven efficacy of insulin treatment in clinical trial settings, fewer than 20% of patients achieved glycaemic goals in this real-world register. However, we could not assess the impacts of healthcare settings (notably reimbursement and healthcare coverage), physicians’ practice behaviours (including knowledge and skills on insulin initiation and intensification), insulin access and affordability, as well as patients’ psychosocial behavioural attributes on these care gaps. Second, the hypoglycaemia assessment in the JADE Register did not capture data on nocturnal hypoglycaemia, or adjustments of insulin dosages and/or regimens during Ramadan fasting. In view of different clinical needs in this special population, 37 a separate study that focuses on the effects of Ramadan fasting is warranted. Third, given that the present study aimed to quantify the impacts of different types of insulin regimens on glycaemic control, we did not compare the effects of human vs analogue insulin. However, existing evidence has consistently reported a similar efficacy in HbA1c reduction, but with a lower risk of hypoglycaemia with the use of analogues insulin compared to human insulin. 29 Last, we acknowledge limitations inherent in cross-sectional surveys that precluded causal inference.

In conclusion, using real-world evidence from the JADE Register, we found that premixed and basal-only regimens were most commonly used by Asian people with type 2 diabetes. While more patients with DKD reported hypoglycaemia, especially those treated with premixed regimen, the low use of basal-bolus regimen and a consistent pattern of poor glycaemic control despite optimal dosage of insulin, call for a better supporting system at patient, provider, organization, and system levels.

**ACKNOWLEDGMENTS**

We thank all participants, JADE collaborators, and their teams who made this study possible.

**CONFLICTS OF INTEREST**

J.C.N.C. is the Chief Executive Officer (on a pro-bono basis) of Asia Diabetes Foundation, a charitable foundation established under the Chinese University of Hong Kong Foundation for developing the JADE Technology. J.C.N.C. has received research grants and/or honoraria for consultancy or giving lectures, from AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi-Sankyo, Eli Lilly, GlaxoSmithKline, Merck Serono, Merck Sharp & Dohme, Novo Nordisk, Pfizer, and Sanofi. A.P.S.K. has received research grants and/or speaker honoraria from Abbott, AstraZeneca, Eli Lilly, Merck Serono, Nestle, and Novo Nordisk. The proceeds have been donated to the Chinese University of Hong Kong, American Diabetes Association, and other charity organizations to support diabetes research and education. J.K. has received speaker honoraria from AstraZeneca, Boehringer Ingelheim, Medtronic, Novo Nordisk, and Sanofi. L.L.L. has received research grants and/or speaker honoraria from Abbott, AstraZeneca, Eli Lilly, Medtronic, Merck Serono, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Procter & Gamble Health, Sanofi, and Servier. T.L., K.W., K.K., and T.T. are employees and...
stockholders of Eli Lilly and Company. Other authors have no conflict of interest to declare.

AUTHOR CONTRIBUTIONS
J.C.N.C. and A.P.S.K. conceptualized the work. A.P.S.K., L.L.L., J.K., W.J., W.H.S., L.S., A.T., K.N.T., K.Y. and J.C.N.C. were involved in the patient recruitment. E.S.H.L. and L.L.L. performed the analysis with support from J.C.N.C. A.P.S.K. wrote the first draft and J.C.N.C. finalized the manuscript. All authors participated in the research methodology, data interpretation, manuscript revision for important intellectual content, and approved the final version of the manuscript. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. J.C.N.C. is the guarantor of this work and, as such, has full access to all the data in the study and takes full responsibility for the integrity and accuracy of the data.

DATA AVAILABILITY
Data cannot be shared publicly as we did not have patients’ consent to release the data in the public domain for open, unrestricted access. Researchers who are interested and meet the criteria for research access to our data may apply for data access via Asia Diabetes Foundation (enquiry@adf.org.hk).

ORCID
Alice P. S. Kong https://orcid.org/0000-0001-8927-6764
Lee-Ling Lim https://orcid.org/0000-0002-6214-6924
Wayne H.-H. Sheu https://orcid.org/0000-0002-8805-8340
Kun-Ho Yoon https://orcid.org/0000-0002-9109-2208
Juliana C. N. Chan https://orcid.org/0000-0003-1325-1194

REFERENCES
1. International Diabetes Federation. IDF Diabetes Atlas. 9th ed. Brussels, Belgium: International Diabetes Federation; 2019.
2. Ohn JH, Kwak SH, Cho YM, et al. 10-year trajectory of beta-cell function and insulin sensitivity in the development of type 2 diabetes: a community-based prospective cohort study. Lancet Diabetes Endocrinol. 2016;4:27-34.
3. Chan WB, Tong PC, Chow CC, et al. The associations of body mass index, C-peptide and metabolic characteristics in Chinese Type 2 diabetic patients. Diabet Med. 2004;21:349-353.
4. Yoon KH, Ko SH, Cho JH, et al. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab. 2003;88:2300-2308.
5. Yeung RO, Zhang Y, Luk A, et al. Metabolic profiles and treatment gaps in young-onset type 2 diabetes in Asia (the JADE programme): a cross-sectional study of a prospective cohort. Lancet Diabetes Endocrinol. 2014;2:935-943.
6. Yang C, Lee HK, Kong APS, Lim LL, Cai Z, Chung ACK. Early-life exposure to endocrine disrupting chemicals associates with childhood obesity. Ann Pediatr Endocrinol Metab. 2018;23:182-195.
7. Chow E, Chan JC. Explaining the high prevalence of young-onset diabetes among Asians and Indigenous Australians. Med J Aust. 2017;207:331-332.
8. Ke C, Lau E, Shah BR, et al. Excess Burden of Mental Illness and Hospitalization in Young-Onset Type 2 Diabetes: A Population-Based Cohort Study. Ann Intern Med. 2019;170(3):145-154.
9. Ting RZ, Nan H, Yu MW, et al. Diabetes-related distress and physical and psychological health in Chinese type 2 diabetic patients. Diabetes Care. 2011;34:1094-1096.
10. Chan JC, Lau ES, Luk AO, et al. Premature mortality and comorbidities in young-onset diabetes: a 7-year prospective analysis. Am J Med. 2014;127:616-624.
11. Hsu L, Magliano DJ, Ranciere F, et al. Impact of age at diagnosis and duration of type 2 diabetes on mortality in Australia 1997–2011. Diabetologia. 2018;61:1055-1063.
12. Zoungas S, Woodward M, Li Q, et al. Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes. Diabetologia. 2014;57:2465-2474.
13. Luk AO, Li X, Zhang Y, et al. Quality of care in patients with diabetic kidney disease in Asia: The Joint Asia Diabetes Evaluation (JADE) Registry. Diabet Med. 2016;33:1230-1239.
14. Kong AP, Xu G, Brown N, So WY, Ma RC, Chan JC. Diabetes and its comorbidities—where East meets West. Nat Rev Endocrinol. 2013;9:537-547.
15. Wang J, Zhang L, Tang SC, et al. Disease burden and challenges of chronic kidney disease in North and East Asia. Kidney Int. 2018;94:22-25.
16. Leung CB, Cheung WL, Li PK. Renal registry in Hong Kong—the first 20 years. Kidney Int Suppl (2011) 2015;5:33–38.
17. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014;37:2864-2883.
18. Chan JCN, Lim LL, Luk AYO, et al. From Hong Kong Diabetes Register to JADE Program to RAMP-DM for Data-Driven Actions. Diabetes Care. 2019;42(11):2022-2031.
19. Davies MJ, D’Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41:2669-2701.
20. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612.
21. Holman RR. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract. 1998;40(Suppl):S21-S25.
22. Li C, Ford ES, Zhao G, Tsai J, Balluz LS, Giles WH. Trends of insulin use among US adults with type 2 diabetes: the Behavioral Risk Factor Surveillance System, 1995–2007. J Diabetes Complications. 2012;26:17-22.
23. Koye DN, Shaw JE, Reid CM, Atkins RC, Reutens AT, Magliano DJ. Incidence of chronic kidney disease among people with diabetes: a systematic review of observational studies. Diabet Med. 2017;34:887-901.
24. Kodama K, Tojjar D, Luk A, Toda K, Patel CJ, Butte AJ. Ethnic differences in the relationship between insulin sensitivity and insulin resistance: a systematic review and meta-analysis. Diabetes Care. 2013;36:1789-1796.
25. Chantelet JM, Gagliardino JJ, Ilkova H, et al. Reasons for discontinuation of insulin therapy: results from the International Diabetes Management Practices Study (IDMPS). Paper presented at: European Association for the Study of Diabetes 54th Annual Meeting; 2–5 October 2018; Berlin, Germany.
26. Lim LL, Lau ESH, Kong APS, et al. Aspects of Multicomponent Integrated Care Promote Sustained Improvement in Surrogate Clinical Outcomes: A Systematic Review and Meta-analysis. Diabetes Care. 2018;41:1312-1320.
27. Russell-Jones D, Pouwer F, Khunti K. Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes Obes Metab. 2018;20:488-496.
28. Cefalu WT, Dawes DE, Gavvak G, et al. Insulin Access and Affordability Working Group: Conclusions and Recommendations. Diabetes Care. 2018;41:1299-1311.
29. Tien KJ, Hung YJ, Chen JF, et al. Basal insulin therapy: Unmet medical needs in Asia and the new insulin glargine in diabetes treatment. J Diabetes Investig. 2019;10:560-570.

30. Kong AP, Yang X, Luk A, et al. Severe hypoglycemia identifies vulnerable patients with type 2 diabetes at risk for premature death and all-site cancer: the Hong Kong diabetes registry. Diabetes Care. 2014;37:1024-1031.

31. Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363:1410-1418.

32. Higgins V, Piercy J, Roughley A, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371-380.

33. Arai K, Takai M, Hirao K, et al. Present status of insulin therapy for type 2 diabetes treated by general practitioners and diabetes specialists in Japan: Third report of a cross-sectional survey of 15,652 patients. J Diabetes Investig. 2012;3:396-401.

34. Snoek FJ, Bremmer MA, Hermanns N. Constructs of depression and distress in diabetes: time for an appraisal. Lancet Diabetes Endocrinol. 2015;3:450-460.

35. Zhang Y, Ting RZ, Yang W, et al. Depression in Chinese patients with type 2 diabetes: associations with hyperglycemia, hypoglycemia, and poor treatment adherence. J Diabetes. 2015;7:800-808.

36. Chan JCN, Bunnag P, Chan SP, et al. Glycaemic responses in Asian and non-Asian people with type 2 diabetes initiating insulin glargine 100units/mL: A patient-level pooled analysis of 16 randomised controlled trials. Diabetes Res Clin Pract. 2018;135:199-205.

37. Goh S-Y, Hussein Z, Rudijanto A. Review of insulin-associated hypoglycemia and its impact on the management of diabetes in Southeast Asian countries. J Diabetes Investig. 2017;8:635-645.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Kong APS, Lew T, Lau ESH, et al. Real-world data reveal unmet clinical needs in insulin treatment in Asian people with type 2 diabetes: the Joint Asia Diabetes Evaluation (JADE) Register. Diabetes Obes Metab. 2020;22:669–679. https://doi.org/10.1111/dom.13950